In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

The choice of treatment approach and outcome in acute myeloid leukemia (AML) depends
on the age of the patient. In younger patients, arbitrarily defined as being younger than 60 …

Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid
cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic …

Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic
progenitor cells and the most common malignant myeloid disorder in adults. The median …

Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission
rate and reduce the risk of relapse, thereby improving survival. Escalation of the …

Introduction: Acute myeloid leukemia (AML) is the most common acute forms of leukemia in
adults. It has a poor long-term survival with a high relapse rate and at relapse, is commonly …

Purpose The goal of this study was to evaluate whether the addition of a purine analog,
cladribine or fludarabine, to the standard induction regimen affects the outcome of adult …

The purpose of this study was to determine the relative merits of idarubicin and daunorubicin
in acute myeloid leukemia (AML) therapy. Thirty-two sites provided 214 previously untreated …

High-dose cytarabine (ara-c) may overcome cytarabine resistance in leukemic blasts. It has
been used as a successful salvage and in postremission therapy but not as initial induction …

Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …